S R Alberts
Overview
Explore the profile of S R Alberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taieb J, Sinicrope F, Pederson L, Lonardi S, Alberts S, George T, et al.
Ann Oncol
. 2023 Aug;
34(11):1025-1034.
PMID: 37619846
Background: The prognostic value of KRAS and BRAF mutations in stage III colon cancer (CC) remains controversial and has never been clearly analyzed in patients with microsatellite instability-high (MSI-H) tumors...
2.
Saberzadeh-Ardestani B, Foster N, Lee H, Shi Q, Alberts S, Smyrk T, et al.
Ann Oncol
. 2022 Aug;
33(11):1159-1167.
PMID: 35963480
Background: Tumor-infiltrating lymphocytes (TILs) are a robust and independent prognostic variable in localized colon cancer. Given reported differences in molecular features and prognosis of right- versus left-sided tumors, we examined...
3.
Lee H, Sha D, Foster N, Shi Q, Alberts S, Smyrk T, et al.
Ann Oncol
. 2020 Mar;
31(4):487-494.
PMID: 32165096
Background: Tumor-infiltrating lymphocytes (TILs), tumor budding, and micropapillary architecture may influence tumor growth and metastatic potential, thereby enhancing prognostic stratification. We analyzed these features and their relative contribution to overall...
4.
Salem M, Yin J, Goldberg R, Pederson L, Wolmark N, Alberts S, et al.
Ann Oncol
. 2020 Feb;
31(4):480-486.
PMID: 32085892
Background: Since 2004, adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX or FLOX) have been the standard of care for patients with resected colon cancer. Herein we examine the change of outcomes...
5.
Yoon H, Bendell J, Braiteh F, Firdaus I, Philip P, Cohn A, et al.
Ann Oncol
. 2020 Jan;
30(12):2016.
PMID: 31893488
No abstract available.
6.
Kim R, Alberts S, Pena C, Genvresse I, Ajavon-Hartmann A, Xia C, et al.
Br J Cancer
. 2018 Jan;
118(4):462-470.
PMID: 29348486
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-α/δ activity that has demonstrated clinical activity and manageable safety when administered as monotherapy in a phase II...
7.
Dienstmann R, Mason M, Sinicrope F, Phipps A, Tejpar S, Nesbakken A, et al.
Ann Oncol
. 2017 Apr;
28(5):1023-1031.
PMID: 28453697
Background: TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers...
8.
Yoon H, Bendell J, Braiteh F, Firdaus I, Philip P, Cohn A, et al.
Ann Oncol
. 2016 Oct;
27(12):2196-2203.
PMID: 27765757
Background: We report the first randomized, Phase II trial of ramucirumab, an anti-vascular endothelial growth factor receptor-2 monoclonal antibody, as front-line therapy in patients with advanced adenocarcinoma of the esophagus...
9.
Perez-Carbonell L, Sinicrope F, Alberts S, Oberg A, Balaguer F, Castells A, et al.
Br J Cancer
. 2015 Jun;
113(1):83-90.
PMID: 26035698
Background: Advances in early detection and treatment have improved outcomes in patients with colorectal cancer (CRC). However, there remains a need for robust prognostic and predictive biomarkers. We conducted a...
10.
Renfro L, Grothey A, Kerr D, Haller D, Andre T, Van Cutsem E, et al.
Ann Oncol
. 2015 Feb;
26(5):950-958.
PMID: 25697217
Background: Post-treatment survival experience of early colon cancer (CC) patients is well described in the literature, which states that cure is probable for some patients. However, comparisons of treated patients'...